Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Ashraf Z, Badros"'
Autor:
Manisha Bhutani, Brandon J. Blue, Craig Cole, Ashraf Z. Badros, Saad Z. Usmani, Ajay K. Nooka, Leon Bernal-Mizrachi, Joseph Mikhael
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract There are significant disparities with regards to incidence, timely diagnosis, access to treatment, clinical trial participation and health care utilization that negatively impact outcomes for African American patients with multiple myeloma.
Externí odkaz:
https://doaj.org/article/d6c25627337a4a6497077d63ec84eae7
Autor:
Andrew Y. Li, Farin Kamangar, Noa G. Holtzman, Aaron P. Rapoport, Mehmet H. Kocoglu, Djordje Atanackovic, Ashraf Z. Badros
Publikováno v:
Cancers, Vol 16, Iss 11, p 2149 (2024)
Circulating plasma cells (CPCs) are detected in most multiple myeloma (MM) patients, both at diagnosis and on relapse. A small subset, plasma cell leukemia (PCL), represents a different biology and has a poor prognosis. In this retrospective analysis
Externí odkaz:
https://doaj.org/article/113032fc72c841ea97d9971b7fcaaf55
Autor:
Sagar Lonial, Ajay K. Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Heather A. Potter, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, Julie Byrne, Joanna Opalinska, January Baron, Trisha Piontek, Ira Gupta, Reza Dana, Asim V. Farooq, Kathryn Colby, Andrzej Jakubowiak
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
Abstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superfic
Externí odkaz:
https://doaj.org/article/f4fbded7918448a587750cd9f85b8f33
Autor:
Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in t
Externí odkaz:
https://doaj.org/article/20b9da9076424d1f8dc1d21eef7bc3c4
Autor:
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 4, Pp 889-911 (2020)
Abstract Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cy
Externí odkaz:
https://doaj.org/article/c9f8e5b32350407bb7943466355dff73
Autor:
Michael E. Kallen, Rima Koka, Zeba N. Singh, Yi Ning, Mehmet H. Kocoglu, Ashraf Z. Badros, Sandrine Niyongere, Vu H. Duong, Ashkan Emadi, Maria R. Baer
Publikováno v:
Leukemia Research Reports, Vol 18, Iss , Pp 100358- (2022)
New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myel
Externí odkaz:
https://doaj.org/article/33542464236147448d22605a7dccfcab
Autor:
Ashraf Z. Badros, Mariam Meddeb, Dianna Weikel, Sunita Philip, Todd Milliron, Rena Lapidus, Lisa Hester, Olga Goloubeva, Timothy F. Meiller, Emmanuel F. Mongodin
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeDefine incidence and risk factors of osteonecrosis of the jaw (ONJ) and explore oral microbial signatures and host immune response as reflected by cytokine changes in saliva and serum in multiple myeloma (MM) patients on bisphosphate (BP) ther
Externí odkaz:
https://doaj.org/article/cb1926a74f7c4390a73d390dbfae1330
Autor:
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 4, Pp 913-915 (2020)
The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf
Externí odkaz:
https://doaj.org/article/71703d0b771d43d492eca3051569effb
Autor:
Edward A. Stadtmauer, Thomas H. Faitg, Daniel E. Lowther, Ashraf Z. Badros, Karen Chagin, Karen Dengel, Malini Iyengar, Luca Melchiori, Jean-Marc Navenot, Elliot Norry, Trupti Trivedi, Ruoxi Wang, Gwendolyn K. Binder, Rafael Amado, Aaron P. Rapoport
Publikováno v:
Blood Advances, Vol 3, Iss 13, Pp 2022-2034 (2019)
Abstract: This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared b
Externí odkaz:
https://doaj.org/article/0da426ccc3774f85a6cbfabc8a4520ed
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e716-e729
Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during